Pulse Biosciences PLSE 深 沪
等待开盘 10-18 09:30:00 美东时间
17.56
-0.010
-0.06%
华盛通- 最 高17.87
- 今 开17.43
- 成交量 12.27万股
- 最 低 17.24
- 昨 收 17.57
- 总市值 11.82亿
- 52周最高 25.00
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 13.7658
- 委 比 1.32%
- 总股本 6729.58万
- 历史最高 45.82
- 量 比 0.75
- 振 幅 3.59%
- 历史最低 1.18
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pulse Biosciences Reveals Promising Study Results
Pulse Biosciences ( ($PLSE) ) has provided an announcement. On October 10, 2025...
10-10 21:28
Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting
Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical SystemPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using
10-10 19:02
7点！医械早播报-9/11
（来源：医疗器械创新网） 01 监管政策与招投标 （一）监管政策 三部门联合建立常态化巡回医疗制度，82 支医疗队赴基层 国家卫健委、国家中医药局、国家疾控局联...
09-11 07:00
Pulse Biosciences Begins First Study Using Nanosecond PFA Tech To Treat Benign Thyroid Nodules
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures
09-02 19:05
Pulse Biosciences Announced A New Publication In The Journal Thyroid, The First-in-human Clinical Feasibility Study Demonstrates The Effectiveness Of Ablation Of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation (nsPFA) Energy
The study was designed to assess the ability of nsPFA energy to provide a safe and effective option for the treatment of symptomatic benign thyroid nodules with minimal side effects. The study was conducted by Professor
08-26 19:05
Pulse Biosciences shares are trading lower after the company reported a Q2 EPS miss.
Pulse Biosciences shares are trading lower after the company reported a Q2 EPS ...
08-13 22:30
Pulse Biosciences Q2 EPS $(0.28) Misses $(0.26) Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 40 percent decrease over losses of $(0.20) per share from
08-13 04:11
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Pulse Biosciences Appoints New VP of Accounting
The latest announcement is out from Pulse Biosciences ( ($PLSE) ). Pulse Biosci...
07-15 05:20
美股大行评级 | 潜在涨幅199.47%！杰富瑞上调Cogent Biosciences目标价至28美元，维持"买入"评级
今日重点评级关注：杰富瑞：维持Cogent Biosciences"买入"评级，目标价从23美元升至28美元；Leerink Partners：维持Cogent Biosciences"跑赢大市"评级，目标价从16美元升至18美元
07-08 09:34
